On­coRe­sponse wraps Se­ries A with $22.5M; Plot­ting IPO, BerGen­Bio part­ners with Mer­ck on can­cer com­bos

→ The im­muno-on­col­o­gy an­ti­body dis­cov­ery com­pa­ny On­coRe­sponse, cre­at­ed by MD An­der­son and Ther­a­clone Sci­ences, just com­plet­ed a long-run­ning Se­ries A with $22.5 mil­lion. The …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.